HDB gains international recognition for its in vivo pharmacology in behavioral research area

HDB has recently formed strategic partnership with an international pharmaceutical company (name remains confidential) in working on the drug discovery for Alzheimer’s disease (AD). HDB applies the Morris Water Maze (MWM) test in the in vivo efficacy evaluation and provides full assessments for the lead compounds. As the typical feature of AD is cognitive deficit in patients, the MWM test is one of the commonly used animal model tests for AD. The test is to assess the cognition or learning ability in several memory deficit animal models, including chemically-induced block of medial temporary lobe, lesion of specific CNS area (NBM), and AD transgenic models. The received recognition for HDB’s MWM tests demonstrates our expertise in CNS research area and indicates the achievement of new progress in behavioral test capabilities.